Boston Scientific Corp. (NYSE: BSX) started the day on Thursday, with a price increase of 0.03% at $75.00, before settling in for the price of $74.98 at the close. Taking a more long-term approach, BSX posted a 52-week range of $48.35-$76.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 8.10%. Meanwhile, its Annual Earning per share during the time was -2.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 13.75%. This publicly-traded company’s shares outstanding now amounts to $1.47 billion, simultaneously with a float of $1.46 billion. The organization now has a market capitalization sitting at $110.26 billion. At the time of writing, stock’s 50-day Moving Average stood at $71.04, while the 200-day Moving Average is $60.52.
Boston Scientific Corp. (BSX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Medical Devices Industry. Boston Scientific Corp.’s current insider ownership accounts for 0.46%, in contrast to 91.68% institutional ownership. According to the most recent insider trade that took place on May 29 ’24, this organization’s EVP&Pres, Periph Intervent sold 63,802 shares at the rate of 75.10, making the entire transaction reach 4,791,447 in total value, affecting insider ownership by 28,022. Preceding that transaction, on May 28 ’24, Company’s EVP& Grp Pres, MedSurg & APAC sold 14,011 for 75.34, making the whole transaction’s value amount to 1,055,590. This particular insider is now the holder of 20,197 in total.
Boston Scientific Corp. (BSX) Earnings and Revenue Records
Boston Scientific Corp.’s EPS increase for this current 12-month fiscal period is 13.75% and is forecasted to reach 2.65 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 12.40% through the next 5 years, which can be compared against the -2.05% growth it accomplished over the previous five years trading on the market.
Boston Scientific Corp. (NYSE: BSX) Trading Performance Indicators
Let’s observe the current performance indicators for Boston Scientific Corp. (BSX). It’s Quick Ratio in the last reported quarter now stands at 1.14. The Stock has managed to achieve an average true range (ATR) of 1.12. Alongside those numbers, its PE Ratio stands at $62.66, and its Beta score is 0.81. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.50. Similarly, its price to free cash flow for trailing twelve months is now 64.94.
In the same vein, BSX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 1.20, a figure that is expected to reach 0.58 in the next quarter, and analysts are predicting that it will be 2.65 at the market close of one year from today.
Technical Analysis of Boston Scientific Corp. (BSX)
If we take a close look at the recent performances of Boston Scientific Corp. (NYSE: BSX), its last 5-days Average volume was 5.32 million that shows plunge from its year to date volume of 6.46 million. During the previous 9 days, stock’s Stochastic %D was recorded 46.58% While, its Average True Range was 1.09.
Raw Stochastic average of Boston Scientific Corp. (BSX) in the period of the previous 100 days is set at 93.24%, which indicates a major rise in contrast to 68.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 13.68% that was lower than 16.95% volatility it exhibited in the past 100-days period.
